{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:57:55Z","timestamp":1762113475163,"version":"3.38.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Accumulating evidence suggests elements within tumors induce exhaustion of effector T cells and infiltration of immunosuppressive regulatory T cells (Tregs), thus preventing the development of durable antitumor immunity. Therefore, the discovery of agents that simultaneously block Treg suppressive function and reinvigorate effector function of lymphocytes is key to the development of effective cancer immunotherapy. Previous studies have shown that TLR ligands (TLRLs) could modulate the function of these T cell targets; however, those studies relied on cell-free or accessory cell-based assay systems that do not accurately reflect in vivo responses. In contrast, we used a human PBMC-based proliferation assay system to simultaneously monitor the effect of TLRLs on T cells (CD4+, CD8+, Tregs), B cells, and NK cells, which gave different and even conflicting results. We found that the TLR7\/8L:CL097 could simultaneously activate CD8+ T cells, B cells, and NK cells plus block Treg suppression of T cells and B cells. The TLRLs TLR1\/2L:Pam3CSK4, TLR5L:flagellin, TLR4L:LPS, and TLR8\/7L:CL075 also blocked Treg suppression of CD4+ or CD8+ T cell proliferation, but not B cell proliferation. Besides CL097, TLR2L:PGN, CL075, and TLR9L:CpG-A, CpG-B, and CpG-C) were strong activators of NK cells. Importantly, we found that Pam3CSK4 could: 1) activate CD4+ T cell proliferation, 2) inhibit the expansion of IL-10+ naturally occurring FOXP3+ Tregs and induction of IL-10+ CD4+ Tregs (IL-10\u2013producing type 1 Treg), and 3) block naturally occurring FOXP3+ Tregs suppressive function. Our results suggest these agents could serve as adjuvants to enhance the efficacy of current immunotherapeutic strategies in cancer patients.<\/jats:p>","DOI":"10.4049\/jimmunol.1203334","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T14:19:10Z","timestamp":1402928350000},"page":"627-634","source":"Crossref","is-referenced-by-count":28,"title":["Targeting of TLRs Inhibits CD4+ Regulatory T Cell Function and Activates Lymphocytes in Human Peripheral Blood Mononuclear Cells"],"prefix":"10.1093","volume":"193","author":[{"given":"Kui Shin","family":"Voo","sequence":"first","affiliation":[{"name":"Department of Genomic Medicine, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bover","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan Lundell","family":"Harline","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsheng","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoshi","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"MedImmune , Gaithersburg, MD 20878"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"MedImmune , Gaithersburg, MD 20878"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,7,15]]},"reference":[{"key":"2025030707220339600_r1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1479-5876-3-18","article-title":"Progress and controversies in developing cancer vaccines","volume":"3","author":"Slingluff","year":"2005","journal-title":"J. Transl. Med."},{"key":"2025030707220339600_r2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2008.07143.x","article-title":"Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials","volume":"142","author":"Park","year":"2008","journal-title":"Br. J. Haematol."},{"key":"2025030707220339600_r3","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"2025030707220339600_r4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0105-2896.2006.00420.x","article-title":"Interleukin-10-secreting type 1 regulatory T cells in rodents and humans","volume":"212","author":"Roncarolo","year":"2006","journal-title":"Immunol. Rev."},{"key":"2025030707220339600_r5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"2025030707220339600_r6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12185-011-0799-6","article-title":"The mechanisms of cancer immunoescape and development of overcoming strategies","volume":"93","author":"Yaguchi","year":"2011","journal-title":"Int. J. Hematol."},{"key":"2025030707220339600_r7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1084\/jem.20011666","article-title":"Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo","volume":"195","author":"Barchet","year":"2002","journal-title":"J. Exp. Med."},{"key":"2025030707220339600_r8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/ni.1791","article-title":"Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis","volume":"10","author":"Murai","year":"2009","journal-title":"Nat. Immunol."},{"key":"2025030707220339600_r9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2249.2010.04091.x","article-title":"Modulation of immune responses through direct activation of Toll-like receptors to T cells","volume":"160","author":"Liu","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"2025030707220339600_r10","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.4049\/jimmunol.1003715","article-title":"TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function","volume":"187","author":"Nyirenda","year":"2011","journal-title":"J. Immunol."},{"key":"2025030707220339600_r11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.1183021","article-title":"Regulation of adaptive immunity by the innate immune system","volume":"327","author":"Iwasaki","year":"2010","journal-title":"Science"},{"key":"2025030707220339600_r12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"2025030707220339600_r13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s12272-012-0802-7","article-title":"Roles of toll-like receptors in cancer: a double-edged sword for defense and offense","volume":"35","author":"Basith","year":"2012","journal-title":"Arch. Pharm. Res."},{"key":"2025030707220339600_r14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1084\/jem.20021633","article-title":"Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide","volume":"197","author":"Caramalho","year":"2003","journal-title":"J. Exp. Med."},{"key":"2025030707220339600_r15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat. Immunol."},{"key":"2025030707220339600_r16","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.4049\/jimmunol.0801167","article-title":"TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal","volume":"182","author":"Mercier","year":"2009","journal-title":"J. Immunol."},{"key":"2025030707220339600_r17","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1113401","article-title":"Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function","volume":"309","author":"Peng","year":"2005","journal-title":"Science"},{"key":"2025030707220339600_r18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.coph.2012.06.002","article-title":"New developments in Toll-like receptor targeted therapeutics","volume":"12","author":"Connolly","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"2025030707220339600_r19","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1600-6143.2011.03558.x","article-title":"Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease","volume":"11","author":"Hippen","year":"2011","journal-title":"Am. J. Transplant."},{"key":"2025030707220339600_r20","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.4049\/jimmunol.178.7.4011","article-title":"NK cells and cancer","volume":"178","author":"Zamai","year":"2007","journal-title":"J. Immunol."},{"key":"2025030707220339600_r21","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.4049\/jimmunol.175.3.1551","article-title":"Direct stimulation of human T cells via TLR5 and TLR7\/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells","volume":"175","author":"Caron","year":"2005","journal-title":"J. Immunol."},{"key":"2025030707220339600_r22","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J. Immunol."},{"key":"2025030707220339600_r23","doi-asserted-by":"crossref","first-page":"13875","DOI":"10.1073\/pnas.95.23.13875","article-title":"Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin","volume":"95","author":"Schimke","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707220339600_r24","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.4049\/jimmunol.175.12.8051","article-title":"Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells","volume":"175","author":"Crellin","year":"2005","journal-title":"J. Immunol."},{"key":"2025030707220339600_r25","doi-asserted-by":"crossref","first-page":"e18833","DOI":"10.1371\/journal.pone.0018833","article-title":"TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo","volume":"6","author":"Yamazaki","year":"2011","journal-title":"PLoS ONE"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/2\/627\/61450324\/1203334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/2\/627\/61450324\/1203334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:46:47Z","timestamp":1741333607000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/193\/2\/627\/7955028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,7,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1203334","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"type":"print","value":"0022-1767"},{"type":"electronic","value":"1550-6606"}],"subject":[],"published-other":{"date-parts":[[2014,7]]},"published":{"date-parts":[[2014,7]]}}}